Abnormal exhaled ethane concentrations in scleroderma

References

• Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial. American Journal of Gastroenterology 2003; 98: 348–353
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. American Journal of Medicine 2004; 116: 595–600
   PubMed Web of Science ®Google Scholar
• Altman DG. Practical statistics for medical research. Chapman & Hall, London 1991; 346
   Google Scholar
• American Rheumatism Association. 1980. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis and Rheumatism 23:581–590.
   PubMedGoogle Scholar
• Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. American Journal of Respiratory Critical Care Medicine 2004; 169: 764–769
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalysed oxidation reactions: implications for pathogenesis. Journal of Experimental Medicine 1997; 185: 71–79
   PubMed Web of Science ®Google Scholar
• Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000; 119: 1340–1347
   PubMed Web of Science ®Google Scholar
• Cope KA, Watson MT, Foster WM, Sehnert SS, Risby TH. Effects of ventilation on the collection of exhaled breath in humans. Journal of Applied Physiology 2004; 96: 1371–1379
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F, Bessard J, Bessard G. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure. Arthritis and Rheumatism 2002; 46: 1319–1323
   PubMedGoogle Scholar
• Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, Pison C. Increased lipid peroxidation in patients with pulmonary hypertension. American Journal of Respiratory Critical Care Medicine 2001a; 164: 1038–1042
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Girolet S, Imbert B, Seinturier C, Stanke-Labesque F, Bessard J, Boignard A, Bessard G, Carpentier PH. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radicals in Biology and Medicine 2005; 38: 98–103
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Marpeau C, Carpentier PH, Imbert B, Hunt M, Stanke-Labesque F, Bessard G. Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. Arthritis and Rheumatism 2001b; 44: 1143–1148
   PubMed Web of Science ®Google Scholar
• Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. British Journal of Rheumatology 1997; 36: 239–243
   PubMedGoogle Scholar
• Emerit I, Filipe P, Meunier P, Auclair C, Freitas J, Deroussent A, Gouyette A, Fernandes A. Clastogenic activity in the plasma of scleroderma patients: a biomarker of oxidative stress. Dermatology 1997; 194: 140–146
   PubMed Web of Science ®Google Scholar
• Generini S, Fiori G, Moggi Pignone A, Matucci Cerinic M, Cagnoni M. Systemic sclerosis. A clinical overview. Advances in Experimental Medicine and Biology 1999; 455: 73–83
   PubMed Web of Science ®Google Scholar
• Girgis RE, Gugnani MK, Abrams J, Mayes MD. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. American Journal of Respiratory Critical Care Medicine 2002; 165: 1587–1591
   PubMed Web of Science ®Google Scholar
• Granger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal ischemia. Gastroenterology 1981; 81: 22–29
   PubMed Web of Science ®Google Scholar
• Greidinger E, Flaherty K, White B, Rosen A, Wigley F, Wise R. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114: 801–807
   PubMed Web of Science ®Google Scholar
• Herrick AL, Worthington H, Rieley F, Clarke D, Schofield D, Braganza JM, Jayson MI. Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. Journal of Rheumatology 1996; 23: 650–653
   PubMed Web of Science ®Google Scholar
• Hummers LK, Wigley FM. Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheumatism Disease Clinics of North America 2003; 29: 293–313
   PubMed Web of Science ®Google Scholar
• Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Annals of Internal Medicine 2004; 140: 37–50
   PubMed Web of Science ®Google Scholar
• Kanoh S, Kobayashi H, Motoyoshi K. Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 2005; 128: 2387–2392
   PubMed Web of Science ®Google Scholar
• Kazui M, Andreoni KA, Norris EJ, Klein AS, Burdick JF, Beattie C, Sehnert SS, Bell WR, Bulkley GB, Risby TH. Breath ethane: a specific indicator of free-radical-mediated lipid peroxidation following reperfusion of the ischemic liver. Free Radicals in Biology and Medicine 1992; 13: 509–515
   PubMed Web of Science ®Google Scholar
• Kazui M, Andreoni KA, Williams GM, Perler BA, Bulkley GB, Beattie C, Donham RT, Sehnert SS, Burdick JF, Risby TH. Visceral lipid peroxidation occurs at reperfusion after supraceliac aortic cross-clamping. Journal of Vascular Surgery 1994; 19: 473–477
   PubMed Web of Science ®Google Scholar
• Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52: 1051–1055
   PubMed Web of Science ®Google Scholar
• Korthuis RJ, Granger DN. Ischemia-reperfusion injury: role of oxygen-derived free radicals. Physiology of oxygen radicals, AE Taylor, S Matalon, PA Ward. American Psychological Society, Baltimore, MD 1986; 217–249
   Google Scholar
• Leclerc M, Bernalier A, Lelait M, Grivet JP. 13C-NMR study of glucose and pyruvate catabolism in four acetogenic species isolated from the human colon. FEMS Microbiology Letters 1997; 146: 199–204
   PubMed Web of Science ®Google Scholar
• Luczynska M, Szkudlarek U, Dziankowska-Bartkowiak B, Waszczykowska E, Kasielski M, Jozefowicz-Okonkwo G, Nowak D. Elevated whole blood chemiluminescence in patients with systemic sclerosis. Clinical and Experimental Rheumatology 2005; 23: 173–179
   PubMed Web of Science ®Google Scholar
• Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circulation Research 1992; 70: 1099–1103
   PubMed Web of Science ®Google Scholar
• Mason RP, Mak IT, Walter MF, Tulenko TN, Mason PE. Antioxidant and cytoprotective activities of the calcium channel blocker mibefradil. Biochemistry and Pharmacology 1998; 55: 1843–1852
   PubMed Web of Science ®Google Scholar
• Medsger TA, Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA , et al. 1999. A disease severity scale for systemic sclerosis: development and testing. Journal of Rheumatology 26: 2159–2167.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, du Bois RM, Kharitonov SA, Barnes PJ. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. American Journal of Respiratory Critical Care Medicine 1998; 158: 1524–1527
   PubMed Web of Science ®Google Scholar
• Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. American Journal of Gastroenterology 2001; 96: 1200–1204
   PubMed Web of Science ®Google Scholar
• Ooi GC, Mok MY, Tsang KW, Wong Y, Khong PL, Fung PC, Chan S, Tse HF, Wong RW, Lam WK, et al. Interstitial lung disease in systemic sclerosis. Acta Radiologica 2003; 44: 258–264
   PubMed Web of Science ®Google Scholar
• Paredi P, Kharitonov SA, Barnes PJ. Elevation of exhaled ethane concentration in asthma. American Journal of Respiratory Critical Care Medicine 2000; 162: 1450–1454
   PubMed Web of Science ®Google Scholar
• Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM, Barnes PJ. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 1999; 115: 1352–1356
   PubMed Web of Science ®Google Scholar
• Risby TH. Volatile organic compounds as markers in normal and diseased states. Disease markers in exhaled breath: basic mechanisms and clinical applications, N Marczin, M Yacoub. IOS Press, Washington, DC 2002; 418
   Google Scholar
• Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S, Bucca C, Morello M, Bergerone S, Bardini D, et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. Journal of Rheumatology 2000; 27: 1693–1698
   PubMed Web of Science ®Google Scholar
• Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, Gabrielli A. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis and Rheumatism 2001; 44: 2653–2664
   PubMed Web of Science ®Google Scholar
• Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, Luchetti MM, Gabrielli A. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. Journal of Investigative Dermatology 1999; 112: 78–84
   PubMed Web of Science ®Google Scholar
• Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pita O, Puddu P, Paganelli R, Russo G. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clinical and Experimental Immunology 2004; 138: 540–546
   PubMed Web of Science ®Google Scholar
• Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003; 124: 2098–2104
   PubMed Web of Science ®Google Scholar
• Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C, Pignone A, Falcini F, Lotti T, Cagnoni M. Oxidative stress in systemic sclerosis. Molecular Cell Biochemistry 1999; 196: 85–91
   PubMed Web of Science ®Google Scholar
• Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM, Gabriele S, Alberto P, Sergio G, Fernanda F, Marco MC. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 2000; 155: 1–15
   PubMed Web of Science ®Google Scholar
• Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis and Rheumatism 1994; 37: 1265–1282
   PubMed Web of Science ®Google Scholar
• Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P, Montella N, Armadans-Gil L, Fonollosa V, Vilardell M. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis and Rheumatism 2000; 43: 894–900
   PubMed Web of Science ®Google Scholar
• Stein CM, Tanner SB, Awad JA, Roberts LJ, 2nd, Morrow JD. 1996. Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis and Rheumatism 39: 1146–1150.
   PubMed Web of Science ®Google Scholar
• Tikly M, Marshall SE, Haldar NA, Gulumian M, Wordsworth P, Welsh KI. Oxygen-free radical scavenger enzyme polymorphisms in systemic sclerosis. Free Radicals in Biology and Medicine 2004; 36: 1403–1407
   PubMed Web of Science ®Google Scholar
• Volpe A, Biasi D, Caramaschi P, Mantovani W, Bambara LM, Canestrini S, Ferrari M, Poli G, Degan M, Carletto A , et al. 2005. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford). [Epub ahead of print] DOI:10.1093/rheumatology/kei151..
   Google Scholar
• Wigley FM. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension. Current Opinions in Rheumatology 1996; 8: 561–568
   PubMedGoogle Scholar
• Wigley FM, Wise RA, Miller R, Needleman BW, Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. Arthritis and Rheumatism 1992; 35: 688–693
   PubMed Web of Science ®Google Scholar
• Yasunobu Y, Oudiz RJ, Sun XG, Hansen JE, Wasserman K. End-tidal PCO2 abnormality and exercize limitation in patients with primary pulmonary hypertension. Chest 2005; 127: 1637–1646
   PubMed Web of Science ®Google Scholar